Is a generic version of Larotrectinib already available for sale?

Larotrectinib, as a highly selective TRK fusion protein inhibitor, has been approved in many countries for the treatment of patients with solid tumors carrying NTRK gene fusions. At present, the drug has been officially launched in my country and has been included in the medical insurance reimbursement catalog. For eligible patients, medical insurance subsidies can be enjoyed according to regulations after a prescription is issued through the hospital, which to a certain extent alleviates the financial pressure caused by high drug costs.

However, the price of larotrectinib’s original drug is still relatively high, with a box of the drug generally costing about 20,000 yuan. Although medical insurance can reimburse part of the cost, in some areas, patients still have to pay a considerable portion of the drug cost out of pocket. Therefore, some patients are also looking at more affordable overseas generic versions as an economic supplement option.

At present, generic drugs of larotrectinib have been launched and put on sale in overseas markets, especially pharmaceutical companies in Laos and other countries have successfully copied the drug. According to public information, the Laotian version of larotrectinib’s generic version only costs a few hundred yuan to more than a thousand yuan, which is far lower than the price of the original drug. More importantly, the ingredients of these generic drugs are basically the same as those of the original drugs, and some patients have reported that their efficacy is highly consistent, making them an important choice for many patients with limited economic conditions.

Overall, although the original drug larotrectinib has been launched in China and is included in medical insurance, the financial burden is still considerable for some patients who require long-term medication. The emergence of overseas generic drugs provides more flexible medication options. Under the guidance of a doctor, patients can choose a treatment plan that suits them based on comprehensive consideration of their condition and financial situation. In the future, as the quality of generic drugs is further standardized and supervision strengthened, their accessibility and trust are expected to further improve.

Reference materials:https://www.vitrakvi.com/